ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Dr. David Reardon on Immunotherapy and Rindopepimut in the Glioblastoma Treatment Paradigm

David Reardon, MD
Published Online:6:42 PM, Wed February 10, 2016


David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses the future of immunotherapy in glioblastoma and how rindopepimut fits into that paradigm. Reardon says rindopepimut is the first immunotherapy to ever show a survival benefit in glioblastoma and hopes a randomized phase III double blind trial with a placebo control arm will allow the drug to make bigger strides in the treatment of the malignancy.

Reardon says the breakthrough of rindopepimut tears down the school of thought that the brain is specifically immuno-privledged and cannot be treated with immunotherapies.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.